Patrick McEnany - Catalyst Pharmaceuticals Co-Founder, Chairman, CEO and Pres

CPRX Stock  USD 16.27  0.52  3.30%   

Chairman

Mr. Patrick James McEnany is the Chairman of the Board, President, Chief Executive Officer of Catalyst Pharmaceutical Partners, Inc. Mr. McEnany is a cofounder of our company and currently serves as our Chairman, President and Chief Executive Officer since 2006.
Age 77
Tenure 18 years
Address 355 Alhambra Circle, Coral Gables, FL, United States, 33134
Phone305 420 3200
Webhttps://www.catalystpharma.com
McEnany was our CEO and a director since our formation in January 2002. He became Chairman and President in March 2006. From 1999 to 2002, Mr. McEnany was a consultant to the pharmaceutical industry. From 1991 to 1997, Mr. McEnany was Chairman and CEO of Royce Laboratories, Inc., a generic pharmaceutical manufacturer. From 1997 to 1998, after the merger of Royce into Watson Pharmaceuticals, Inc., Mr. McEnany served as president of the whollyowned Royce Laboratories subsidiary and vice president of corporate development for Watson Pharmaceuticals, Inc. From 1993 to 1997, he also served as vice chairman and a director of the National Association of Pharmaceutical Manufacturers. He currently serves on the board of directors of the Jackson Health Foundation and the Humane Society of Greater Miami, and over the last 30 years has served as a director for numerous public companies. The Board believes the characteristics that qualify Mr

Catalyst Pharmaceuticals Management Efficiency

The company has return on total asset (ROA) of 0.1283 % which means that it generated a profit of $0.1283 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.2075 %, meaning that it created $0.2075 on every $100 dollars invested by stockholders. Catalyst Pharmaceuticals' management efficiency ratios could be used to measure how well Catalyst Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is likely to rise to 0.23 in 2024. Return On Assets is likely to rise to 0.16 in 2024. At this time, Catalyst Pharmaceuticals' Total Assets are fairly stable compared to the past year. Total Current Assets is likely to rise to about 230.3 M in 2024, whereas Other Assets are likely to drop 0.95 in 2024.
The company currently holds 3.56 M in liabilities with Debt to Equity (D/E) ratio of 0.02, which may suggest the company is not taking enough advantage from borrowing. Catalyst Pharmaceuticals has a current ratio of 10.57, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Catalyst Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Catalyst Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Catalyst Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Catalyst to invest in growth at high rates of return. When we think about Catalyst Pharmaceuticals' use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 6 records

CHAIRMAN Age

Nick CaporellaNational Beverage Corp
88
David SimonSimon Property Group
62
Kornelis StormAnheuser Busch Inbev
73
Thomas RichardsCDW Corp
63
Martin BarringtonAnheuser Busch Inbev
68
Herbert SimonSimon Property Group
86
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida. Catalyst Pharm operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 76 people. Catalyst Pharmaceuticals (CPRX) is traded on NASDAQ Exchange in USA. It is located in 355 Alhambra Circle, Coral Gables, FL, United States, 33134 and employs 167 people. Catalyst Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Catalyst Pharmaceuticals Leadership Team

Elected by the shareholders, the Catalyst Pharmaceuticals' board of directors comprises two types of representatives: Catalyst Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Catalyst. The board's role is to monitor Catalyst Pharmaceuticals' management team and ensure that shareholders' interests are well served. Catalyst Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Catalyst Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
Pete Sr, Vice Sales
Mary Coleman, VP Relations
Donald Denkhaus, Director
Gary MD, Chief Officer
Jeffrey Carmen, Executive Officer
Charles OKeeffe, Lead Independent Director
Bernardino Mosquera, Vice President - Clinical Operations
Alicia Grande, CFO, Vice President Treasurer
David Tierney, Independent Director
Preethi Sundaram, Chief Officer
Daniel Brennan, Chief Commercial Officer
Philip Coelho, Independent Director
Richard Daly, Interim Chief Commercial Officer, Director and Member of Nominating and Corporate Governance Committee
Philip Schwartz, Co Sec
CMA CPA, VP, Officer
Richard MBA, CEO President
Stanley MD, Senior Discovery
Michael CPA, Executive CFO
Gary Ingenito, Chief Medical Officer
David Connolly, IR Contact Officer
Douglas Winship, Vice President - Regulatory Operations
Patrick McEnany, Co-Founder, Chairman, CEO and Pres
Steven Miller, COO and Chief Scientific Officer
Brian Elsbernd, Chief Compliance Officer, Chief Legal Officer
David Caponera, Vice President - Patient Advocacy & Reimbursement
David Muth, Chief Commercial Officer and Executive VP
Brian JD, Chief Officer

Catalyst Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Catalyst Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Pair Trading with Catalyst Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Catalyst Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Catalyst Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving against Catalyst Stock

  0.54VBIV VBI Vaccines Financial Report 20th of May 2024 PairCorr
  0.49MRK Merck Company Fiscal Quarter End 31st of March 2024 PairCorr
  0.46TFX Teleflex Incorporated Financial Report 2nd of May 2024 PairCorr
The ability to find closely correlated positions to Catalyst Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Catalyst Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Catalyst Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Catalyst Pharmaceuticals to buy it.
The correlation of Catalyst Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Catalyst Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Catalyst Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Catalyst Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Catalyst Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Catalyst Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Catalyst Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Catalyst Pharmaceuticals Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Catalyst Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For more information on how to buy Catalyst Stock please use our How to Invest in Catalyst Pharmaceuticals guide.
You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.

Complementary Tools for Catalyst Stock analysis

When running Catalyst Pharmaceuticals' price analysis, check to measure Catalyst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Catalyst Pharmaceuticals is operating at the current time. Most of Catalyst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Catalyst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Catalyst Pharmaceuticals' price. Additionally, you may evaluate how the addition of Catalyst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Stocks Directory
Find actively traded stocks across global markets
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Money Managers
Screen money managers from public funds and ETFs managed around the world
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Is Catalyst Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Catalyst Pharmaceuticals. If investors know Catalyst will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Catalyst Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.346
Earnings Share
0.63
Revenue Per Share
3.747
Quarterly Revenue Growth
0.82
Return On Assets
0.1283
The market value of Catalyst Pharmaceuticals is measured differently than its book value, which is the value of Catalyst that is recorded on the company's balance sheet. Investors also form their own opinion of Catalyst Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Catalyst Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Catalyst Pharmaceuticals' market value can be influenced by many factors that don't directly affect Catalyst Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Catalyst Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Catalyst Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Catalyst Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.